|
**Overview**: **Hemoglobin HPLC Electrophoresis Profile****Introduction**: The Hemoglobin HPLC Electrophoresis Profile is a diagnostic tool designed to screen for hemoglobinopathies using whole blood samples. Associated with conditions like sickle cell disease and thalassemia, these disorders present with anemia, jaundice, and severe complications if untreated, particularly in individuals with suspected hemoglobin disorders. Per the 2023 Hematology guidelines, the test employs hematology with HPLC/electrophoresis technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for anemia screening in clinical settings. This diagnostic falls under anemia screening and targets individuals with suspected hemoglobinopathies, addressing the challenge of accurate hemoglobin variant assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its blood-based approach ensures reliable detection.**Other Names**: Hb HPLC Pfl.**FDA Status**: FDA approved, CLIA certified for hematology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1980s by hematology labs, this test advanced hemoglobinopathy diagnostics.**Purpose**: The test screens for 12 parameters including Hemoglobin A to guide hemoglobinopathy assessment, assess hemoglobin variants, and inform treatment and prevention strategies.**Test Parameters**: 1. Hemoglobin A, 2. Hemoglobin A2, 3. Hemoglobin F, 4. Hemoglobin S, 5. Hemoglobin C, 6. Hemoglobin D, 7. Hemoglobin E, 8. Total Hemoglobin, 9. Hematocrit, 10. MCV, 11. MCH, 12. Peripheral Smear.**Pretest Condition**: No fasting required; patients should report anemia, jaundice, or recent hemoglobin symptoms.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not specified, immediate processing recommended to preserve cell integrity.**Medical History**: Patients should provide details on anemia, jaundice, prior hemoglobin reactions, or family history of hemoglobinopathies, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hemoglobinopathies including organ damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using HPLC/electrophoresis and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent transfusions can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible hemoglobinopathies, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early disease stages.**Specialist Consultation**: General practitioners or specialists in hematology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Genetic testing or hemoglobin electrophoresis for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Hematology Guidelines 2023, Journal of Hematology 2024, Biochemistry 2025. |
